Brief: JDS1, LLC terminates proxy contest at Catalyst’s 2022 annual meeting
11/08/2022 11:07
Aug 11 (Reuters) - Catalyst Biosciences Inc CBIO.O :
* JDS1, LLC TERMINATES PROXY CONTEST AT CATALYST’S 2022
ANNUAL
MEETING
Source text for Eikon: ID:nBw76d7xma
Further company coverage: CBIO.O
Recent news on Gyre Therapeutics
See all newsBrief: Gyre Therapeutics - Enters Employment Agreement With Ying Luo As CEO - SEC Filing
Gyre Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Gyre Therapeutics, Inc. expected to post a loss of 13 cents a share - Earnings Preview
Brief: Gyre Therapeutics Reports Second Quarter 2026
Gyre Therapeutics Q2 revenue beats estimates on higher ETUARY sales volumes